Septerna Inc. has closed a US$150 million series B financing and will use the funds to continue development of its portfolio of G protein-coupled receptor (GPCR)-targeted, oral small-molecule drug candidates, including advancement of its lead program targeting the parathyroid hormone 1 receptor (PTH1R) to clinical proof of mechanism.
Crossbow Therapeutics Inc. has launched with US$80 million in series A funding. The financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR).
Taking aim at the elusive place where stubborn cancer cells multiply, Crossbow Therapeutics Inc. has launched with $80 million in funds through a series A round. The Cambridge, Mass.-based company plans to advance its novel therapies, which mimic T-cell receptors and target peptide-loaded major histocompatibility complexes on cancer cells. If all goes well, the first product will be in the clinic in 2025.
Kelun-Biotech Biopharmaceutical Co. Ltd. raised HK$1.36 billion (US$174 million) in an IPO in Hong Kong to support its push into the increasingly competitive antibody-drug conjugate (ADC) market in China.
Sinotau Pharmaceutical Group raised ¥1.1 billion (US$152 million) in a financing round to develop its radiopharmaceutical drugs for diagnostic and therapeutic interventions.
Worg Pharmaceuticals (Zhejiang) Co. Ltd. raised ¥1.1 billion (US$152 million) in a series C round to develop its therapies for allergy and autoimmune diseases, as well as to expand into the global market.
Coloplast A/S agreed to acquire wound care company Kerecis Ehf for up to $1.3 billion in a bid to strengthen its presence in the high-growth, U.S.-centric biologics segment. Kerecis has developed a technology which uses intact fish skin from Atlantic cod to treat chronic wounds. It has around 5% share of the U.S. biologics market.
RSS
